118. Myelomeningocele Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 6 / Drugs : 9 - (DrugBank : 4) / Drug target genes : 2 - Drug target pathways : 12
Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)
Anticholinergic
Assiut University
2024 - NCT06301802 Egypt
Atosiban
University of Sao Paulo General Hospital
2017 - NCT04468568 Brazil
Botulinum A toxin
University of Aarhus
2005 Phase 4 NCT00175123 Denmark
CIC
Assiut University
2024 - NCT06301802 Egypt
Contrast enhanced voiding urosonography with urodynamic testing
University of Virginia
2021 - NCT04738539 United States
Monitor
Marmara University
2016 - NCT04186338 -
Placental mesenchymal stem cells seeded ON A commercially available dural graft extracellular matrix
University of California, Davis
2021 Phase 1/Phase 2 NCT04652908 United States
Terbutaline
University of Sao Paulo General Hospital
2017 - NCT04468568 Brazil
Untreated contemporaneous cohort
University of California, Davis
2021 Phase 1/Phase 2 NCT04652908 United States
Assiut University
2024 - NCT06301802 Egypt
Atosiban
University of Sao Paulo General Hospital
2017 - NCT04468568 Brazil
Botulinum A toxin
University of Aarhus
2005 Phase 4 NCT00175123 Denmark
CIC
Assiut University
2024 - NCT06301802 Egypt
Contrast enhanced voiding urosonography with urodynamic testing
University of Virginia
2021 - NCT04738539 United States
Monitor
Marmara University
2016 - NCT04186338 -
Placental mesenchymal stem cells seeded ON A commercially available dural graft extracellular matrix
University of California, Davis
2021 Phase 1/Phase 2 NCT04652908 United States
Terbutaline
University of Sao Paulo General Hospital
2017 - NCT04468568 Brazil
Untreated contemporaneous cohort
University of California, Davis
2021 Phase 1/Phase 2 NCT04652908 United States